Brought to you by 
Novartis gets access to UPenn's immunotherapies and technology
09 Nov 2021
Executive Summary
Novartis AG has teamed up with the University of Pennsylvania to develop cellular immunotherapies for cancer. The Big Pharma gets exclusive rights to UPenn’s chimeric antigen receptor technologies as well as the drug candidates that result from its use, including CART19 which targets the CD19 protein. It was discovered by the university's Carl June, MD, and is expected to start Phase II in Q4 2012.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis gets access to UPenn's immunotherapies and technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice